Developing mouthswab patient friendly testing combined with determining African/Asian incidence of a biomarker to reduce risks of adverse birth outcomes using a novel pharmacogenomic test

COVID 19要求尽可能限制与患者的面对面接触，因此获得临床试验样本非常困难。该项目包括使用口腔拭子获取患者DNA，对与不良出生结局相关的生物标志物的发生率进行基因分型，并将结果纳入大型临床研究。这些患者在大城市医院的分娩中占很高比例，并且由于未知的原因，具有更高的不良出生结果风险。口腔拭子将允许患者进行测试，而无需访问诊所提供血液样本。

COVID19 has required face to face contact with patients to be as limited as possible thus making obtaining clinical trial samples very difficult.The project comprises using mouthswabs to gain access to patients DNA to genotype for the incidence of a biomarker associated with adverse birth outcomes and include the results in a large clinical study. These patients account for a high proportion of deliveries in large city hospitals and have a higher risk of adverse birth outcomes for reasons as yet unknown. Mouthswabs will allow patients to be tested without need of visiting clinics to provide a blood sample.